Asparaginase Escherichia coli
- Generic Name
- Asparaginase Escherichia coli
- Brand Names
- Rylaze, Spectrila
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9015-68-3
- Unique Ingredient Identifier
- G4FQ3CKY5R
- Background
Asparaginase derived from Escherichia coli (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from E. coli has clinically shown to exh...
- Indication
Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-11-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT06676293
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Taoyuan City, Taiwan
Ma-Spore ALL 2020 Study
- Conditions
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 500
- Registration Number
- NCT06336395
- Locations
- 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Kuala Lumpur, Malaysia
🇸🇬KK Women's and Children's Hospital, Singapore, Singapore
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- wang, jianxiang
- Target Recruit Count
- 50
- Registration Number
- NCT04440267
- Locations
- 🇨🇳
HBDH, Tianjin, Tianjin, China
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: AsparaginaseDrug: Asparaginase Erwinia chrysanthemiProcedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyBehavioral: Cogstate Assessment BatteryProcedure: Computed TomographyDrug: CytarabineDrug: EtoposideDrug: Dexrazoxane HydrochlorideDrug: Daunorubicin HydrochlorideOther: Fludeoxyglucose F-18Drug: Gemtuzumab OzogamicinDrug: Gilteritinib FumarateDrug: Liposome-encapsulated Daunorubicin-CytarabineDrug: MethotrexateProcedure: Magnetic Resonance ImagingDrug: Mitoxantrone HydrochlorideProcedure: Positron Emission TomographyDrug: Therapeutic Hydrocortisone
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1400
- Registration Number
- NCT04293562
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
The Association Between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in NOPHOALL 2008
- Conditions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Aarhus University Hospital
- Target Recruit Count
- 1248
- Registration Number
- NCT04187248
- Locations
- 🇩🇰
Aarhus University Hospital, Department of Pediatrics Skejby Hospital, Aarhus, Aarhus N, Denmark
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2024-02-22
- Target Recruit Count
- 31
- Registration Number
- NCT03817320
- Locations
- 🇺🇸
Texas Children's Hospital/Baylor University, Houston, Texas, United States
🇺🇸Children's Hospital Orange County, Orange, California, United States
🇺🇸Cook Children's Medical Center, Fort Worth, Texas, United States
Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2022-03-16
- Target Recruit Count
- 7
- Registration Number
- NCT03668392
- Locations
- 🇮🇹
Asl Roma 2, Ospedale S. Eugenio- Ospedale S.Eugenio - Uoc Ematologia, Roma, Italy
🇮🇹Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica, Ancona, Italy
🇮🇹Aso S. Croce E Carle - Cuneo - Sc Ematologia, Cuneo, Italy
SIMPLE Chemotherapy for NK Lymphoma/Leukaemia
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 68
- Registration Number
- NCT03623087
- Locations
- 🇭🇰
The University of Hong Kong, Hong Kong, Hong Kong
Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2018-06-11
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 50
- Registration Number
- NCT03071822
- Locations
- 🇭🇰
The University of Hong Kong, Hong Kong, Hong Kong
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 500
- Registration Number
- NCT02894645
- Locations
- 🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Subang Jaya, Malaysia
🇸🇬National University Hospital, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.